Affiliation:
1. Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany
Abstract
Intraductal carcinoma of the prostate is most commonly associated with high-grade invasive prostate cancer. However, isolated IDC-P without adjacent cancer or high-grade cancer is also well known. Common genetic alterations present in IDC-P with adjacent high-grade prostate cancer are those described in high-grade tumors, such as PTEN loss (69–84%). In addition, the rate of LOH involving TP53 and RB1 is significantly higher. IDC-P is common in the TCGA molecular subset of SPOP mutant cancers, and the presence of SPOP mutations are more likely in IDC-P bearing tumors. IDC-P without adjacent high-grade cancers are by far less common. They are less likely to have PTEN loss (47%) and rarely harbor an ERG fusion (7%). Molecular alterations that may predispose a person to the development of IDC-P include the loss of BRCA2 and PTEN as well as mutations in SPOP. However, the causative nature of these genetic alterations is yet to be validated.
Reference55 articles.
1. Pantazopoulos, H., Diop, M.-K., Grosset, A.-A., Rouleau-Gagné, F., Al-Saleh, A., Boblea, T., and Trudel, D. (2022). Intraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait. Cancers, 14.
2. International Agency for Research on Cancer (2022). Urinary and Male Genital Tumours.
3. Moch, H., Humphrey, P.A., Ulbright, T.M., and Reuter, V.E. (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs.
4. The role of intraductal carcinoma in the natural history of prostatic adenocarcinoma;McNeal;Eur. Urol.,2001
5. Zur Frage des Prostatakrebses;Gaynor;Virchows Arch. Path. Anat.,1938